Browsing Tag
Repligen Corporation
2 posts
Wall Street welcomes Repligen’s $1.5bn BioLife deal, but integration now matters
Repligen’s $1.5bn BioLife deal targets recurring cell therapy revenue. See why investors welcomed the bet and where execution risk remains.
Gold, energy, and rare earth stocks dominate U.S. market gains amid trade pressures and fed uncertainty
Explore why gold, energy, and rare earth companies led U.S. stock market gains on April 16, 2025, as investors reacted to trade tensions and rate policy fears.